Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000505

Drug Information
NameMexiletine
Synonyms1-methyl-2-(2,6-xylyloxy)ethanamine; KBio2_004650; BSPBio_002254; KOE-1173; NCGC00015659-04; BSPBio_000022; SBB070242; KO-1173; BRN 2092205; 31828-71-4; CID4178; 5370-01-4 (hydrochloride); Spectrum5_001279; Lopac0_000784; 2-(2-Aminopropoxy)-1,3-DiMethyl-Benzene Hydrochloride; LS-68257; KBioSS_002082; C07220; Spectrum3_000727; KO1173; D08215; DB00379; EINECS 250-825-7; Mexiletina [INN-Spanish]; CHEBI:6916; Prestwick1_000241; CHEBI:115958; KBio1_000834; Mexityl; Prestwick0_000241; SPBio_002241; 1-Methyl-2-(2,6-xylyloxy)ethylamine; BRD-A64092382-003-04-3; Mexiletine HCL; UNII-1U511HHV4Z; I01-6374; NCGC00162253-02; 1-(2,6-Dimethylphenoxy)-2-propanamine; Prestwick3_000241; Mexiletine (INN); MolPort-001-790-944; NINDS_000834; (2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane; Mexiletine; AC1L1HL7; 1-(2,6-dimethylphenoxy)propan-2-amine; 2-Propanamine, 1-(2,6-dimethylphenoxy)-; (+-)-1-(2,6-dimethylphenoxy)propan-2-amine; Mexiletine [INN:BAN]; KBio2_002082; NCGC00162253-01; KBio2_007218; Mexiletinum; Spectrum_001602; CHEMBL558; Mexiletinum [INN-Latin]; 1-(2',6'-Dimethylphenoxy)-2-aminopropane; KBioGR_001270; KBio3_001474; Mexilitine; Mexiletene; BPBio1_000026; AC1Q2BC5; IDI1_000834; 2-(2-aminopropoxy)-1,3-dimethylbenzene; ETHYLAMINE, 1-METHYL-2-(2,6-XYLYLOXY)-; Prestwick2_000241; Mexiletina; Spectrum4_000795; AC1Q2BC6; DivK1c_000834; AB00053683
Trade NameMexitil
IndicationVentricular arrhythmias
[ICD9: 427.1   ICD10: I47.2]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H
3
InChIKeyVLPIATFUUWWMKC-UHFFFAOYSA-N
Canonical SMILESCC1=C(C(=CC=C1)C)OCC(C)N    
Therapeutic ClassAnti-Arrhythmia Agents
CAS NumberCAS 31828-71-4
FormulaC11H17NO
PubChem Compound IDCID 4178.
PubChem Substance IDSID 9429.
SuperDrug ATC IDC01BB02
SuperDrug CAS ID031828714;
TargetSodium channel protein type 5 subunit alphaBlocker[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074377 To Reference
Ref 2Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543